MedTrace Logo

Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression

NCT04798612 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2023-08-18

No results posted yet for this study

Summary

The aim of this randomized double-blinded placebo-controlled phase 2 study is to determine efficacy of preoperative treatment with interferon-alfa2a in patients with pMMR colon cancer on perioperative immune suppression and infiltration of lymphocytes in the primary tumor.

Conditions

Interventions

DRUG

Pegasys

45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between

DRUG

Saline

0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-14
Primary Completion
2025-08-01
Completion
2025-12-01

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04798612 on ClinicalTrials.gov